Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
Kezar Life Sciences (Nasdaq: KZR), a clinical-stage biotech company focused on immune-mediated disease therapeutics, has announced its participation in two major investor conferences in September 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
-
Event: 2025 Wells Fargo Healthcare Conference
Location:Boston, MA
Date/Time: Friday, September 5, 2025, at 11:00 am ET
Format: Fireside Chat
-
Event: H.C. Wainwright 27th Annual Global Investment Conference
Location:New York, NY
Date/Time: Monday, September 8, 2025, at 7:00 am ET
Format: Pre-Recorded On-Demand Presentation
A webcast of the fireside chat at the 2025 Wells Fargo Healthcare Conference will be available on the “Events & Presentations” section of the Company’s website at www.kezarlifesciences.com. Following the event, an archived webcast will be available on the Kezar website for 90 days.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit www.kezarlifesciences.com, and follow us on LinkedIn, Facebook, Twitter and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250828473829/en/
Investor and Media Contact:
Gitanjali Jain
Senior Vice President, Investor Relations and External Affairs
Kezar Life Sciences, Inc.
gjain@kezarbio.com
Source: Kezar Life Sciences